St. Jude Medical halts Enlightn IV trial

Tue, 12/10/2013 - 3:30pm
Mass Device

St. Jude Medical halts the Enlightn IV trial of its renal denervation technology just a few months after getting the green light to begin enrollment.

St. Jude Medical halts Enlightn IV trial

St. Jude Medical (NYSE:STJ) is calling off the Enlightn IV trial of the next generation of its renal denervation technology, just a few months after it began.

The trial of St. Jude's multi-electrode Enlightn device was slated to enroll about 590 patients between the ages of 18 and 80 with high blood pressure that isn't well-managed with drugs.

But concerns that a competing Medtronic (NYSE:MDT) device, the Symplicity, could reach the U.S. market led St. Jude to spike the Enlightn IV trial, which it launched in May. Having another technology on the market would make it tough to interest patients in the trial, which might see them enrolled in the sham arm of the study, a company spokeswoman told in an email.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.